WOBURN, Mass., Sept. 18 BioVex Inc, a biotechnologycompany developing clinical stage treatments for cancer and the prevention ofinfectious disease, today announced that Philip Astley-Sparke, President andCEO, is scheduled to present at the UBS Global Life Sciences Conference onThursday, September 25th at 8:00 A.M. The conference is being held at theGrand Hyatt New York in New York, NY.
BioVex is a privately held biotechnology Company based in Woburn, MA. TheCompany is developing a new class of potent biologics for the treatment ofcancer and prevention of infectious disease.
The Company's lead cancer technology platform, OncoVEXGM-CSF is afirst-in-class oncolytic, or cancer destroying virus technology.OncoVEXGM-CSF works by: replicating and spreading within solid tumors, causingthe death of cancer cells; while stimulating the immune system to destroymetastatic deposits. Both modes of action have been clearly validated in theclinic, where multiple patients with metastatic disease progressing atenrollment have been declared disease free. BioVex believes OncoVEXGM-CSF hasthe potential to become a leading standard of care in the treatment of manysolid tumors based on the strength of clinical data generated to date, coupledwith a benign side effect profile.
BioVex is currently completing a Phase II clinical trial of OncoVEXGM-CSFfor melanoma and Phase I/II clinical trials for head & neck cancer andpancreatic cancer. Earlier this year, the Company announced that the FDAapproved the design of a single, pivotal Phase III clinical trial evaluatingOncoVEXGM-CSF in previously treated patients with metastatic melanoma underthe Special Protocol Assessment (SPA) procedure and plans to make a second SPAsubmission for head & neck cancer later in the year. BioVex intends to beginits Phase III trial for OncoVEXGM-CSF in melanoma in the first quarter of2009.
BioVex recently announced that the UK Medicines and Healthcare productsRegulatory Agency (MHRA) has accepted the Company's Clinical Trial Applicationto conduct a Phase I clinical study testing the safety and immunogenicity ofits lead infectious disease candidate for genital herpes, ImmunoVEXHSV2, anovel, live-attenuated vaccine. In pre-clinical studies, ImmunoVEXHSV2completely prevented all symptoms of genital herpes and triggered a powerfulimmune response, suggesting that ImmunoVEX HSV2 may be more potent than otherHSV-2 vaccines for which data has been published.
For further information, please go to www.biovex.com.
SOURCE BioVex Inc